Ginkgo Bioworks Holdings, Inc.

NYSE•DNA

執行長: Dr. Jason Kelly Ph.D.

板塊: Healthcare

行業: Biotechnology

上市日期: 2021-04-19

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

聯絡資訊

27 Drydock Avenue, 8th Floor, Boston, MA, 02210, United States

877-422-5362

www.ginkgobioworks.com

市值

$405.35M

本益比 (TTM)

-1.2

4.6

股息率

52周最高

$17.58

52周最低

$5.00

52周範圍

13%

排名66Top 96.8%

1.5

F-Score

改良版 Piotroski 分析

基於 6 年期基本面

疲弱 • 1.5 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2020-2025

財務儀表板

Q4 2025 數據

營業收入

$33.40M+0.00%

近4季度走勢

每股收益

-$1.43+0.00%

近4季度走勢

自由現金流

-$63.00M+0.00%

近4季度走勢

2025 Annual 財報亮點

核心亮點

Operating Expenses Decline Total operating expenses fell $301.3M to $485.4M in 2025; R&D expenses decreased $180.3M reflecting restructuring.

Net Loss Narrows Net loss improved $234.3M to $(312.8)M in 2025, driven by lower operating costs and no goodwill impairment recorded.

Operating Cash Burn Reduced Net cash used in operating activities decreased $148.5M to $(171.1)M in 2025, reflecting successful cost control measures.

Biosecurity Segment Sale Agreed Entered agreement February 2026 to sell Biosecurity Business for approximately 20% equity stake in Tower Biosecurity.

關注風險

Continued Net Losses Expected Company has history of net losses; expects continued losses for foreseeable future, may never achieve profitability or sustain growth.

Critical Supplier Dependency Risks Reliance on limited, single-source suppliers for critical lab supplies exposes business to supply chain delays and cost risks.

Revenue Concentration Risk Significant revenue concentration exists; one Cell Engineering customer accounted for 15% of total 2025 revenue.

Synthetic Biology Technology Risk Rapidly changing synthetic biology technology risks making current platform, programs, and services obsolete or non-competitive.

未來展望

Investing in Tools Offerings Anticipates expenditures exceeding revenue; plans to further invest in and expand proprietary tools offerings and platform capabilities.

Expanding AI/ML Capabilities Continue developing and deploying generative AI and machine learning tools to enhance biological R&D efficiency and throughput.

Need for Future Capital Expects continued net losses, requiring substantial additional capital to fund business development and platform expansion.

Maintain Multi-Class Structure Expects to maintain concentrated voting power via multi-class stock structure to prioritize long-term goals over short-term results.

同行對比

營業收入 (TTM)

IOVA

$263.50M

+60.6%

ARVN

$262.60M

-0.3%

VALN

$198.55M

+13.5%

毛利率 (最新季度)

VIR

672.1%

-54902.1pp

IOVA

215.9%

+65.9pp

DNA

124.4%

-21.7pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
IOVA	$1.41B	-4.4	-54.5%	5.3%
NRIX	$1.41B	-5.8	-57.5%	8.1%
VIR	$1.33B	-3.0	-49.3%	18.6%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

-11.6%

增長承壓

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

現金流需要關注

深度研究

下次財報:2026年5月5日

每股收益:-

營業收入:$41.50M

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料